Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03740776
  4. Details
NCT03740776 Clinical Trial

The Eosinophils Percentage Predicts In-hospital Major Adverse Cardiac Events in STEMI Patients After PCI

ST Elevation Myocardial Infarction Clinical Trial

Official title:
The Eosinophils Percentage Predicts In-hospital Major Adverse Cardiac Events in Patients With ST-elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03740776
Other study ID # 2018-35
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 1, 2015
Est. completion date November 1, 2018

Study information
Verified date November 2018
Source Chongqing Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Eosinophils (EOS) in peripheral blood are significantly decreased in ST-segment elevation myocardial infarction (STEMI) and the reduced EOS indicates severe myocardial damage. Whether EOS is a good predictor for in-hospital major adverse cardiac events (MACEs) of patients with ST-segment elevation myocardial infarction remains unknown. The aims of this study was to evaluate prognostic role of EOS for in-hospital MACEs in STEMI patients who have undergone primary percutaneous coronary intervention (PCI)

Description:

The investigators retrospectively analyzed the clinical data of 518 patients with STEMI after PCI. MACEs were defined as cardiac arrest, cardiac rapture, malignant arrhythmia and cardiac death. The receiver operating characteristic (ROC) curves were used to demonstrate the prognostic value of EOS% in in-hospital MACEs. All patients were divided into 2 groups according to the best cut-off EOS% value, including reduced EOS% group and control group. Cox regression analyses and KM survival curve were used to calculate the correlated between EOS with in-hospital MACEs.

Recruitment information / eligibility
Status Completed
Enrollment 2
Est. completion date November 1, 2018
Est. primary completion date August 1, 2017
Accepts healthy volunteers
Gender All
Age group 20 Years to 85 Years
Eligibility Inclusion Criteria:

1. Patients with STEMI who underwent PCI within 12 hours from symptom onset

2. Patients from whom informed consent has been properly obtained in writing prior to start of the trial.

Exclusion Criteria:

1. Patients with previous myocardial infarction, congenital heart disease

2. Patients with liver disease, and renal failure

3. Patients with immunologic disease, malignant tumors, pregnancy, infection caused by various pathogens, chronic inflammatory disease, trauma.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Dongying Zhang

Outcome
Type Measure Description Time frame Safety issue
Primary major adverse cardiac events the relationship between reduced eosinophils percentage and in-hospital MACE The median time of 7 days
See also
  Status Clinical Trial Phase
Recruiting NCT05601999 - Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction Phase 3
Recruiting NCT06147986 - Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients Phase 2
Not yet recruiting NCT05881382 - Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction Phase 3
Enrolling by invitation NCT02615015 - SNPs in the DNase 1 Gene Impair Its Activity and Are Increased in a STE-ACS Patient Cohort Compared to Healthy Controls N/A
Recruiting NCT05812963 - IVUS Versus FFR for Non-infarct Related Artery Lesions in Patients With Multivessel Disease and Acute STEMI N/A
Recruiting NCT05554588 - Intrathrombus Thrombolysis Versus Aspiration Thrombectomy During Primary PCI N/A
Recruiting NCT05450757 - Shanghai ST-segment Elevation Myocardial Infarction Cohort
Active, not recruiting NCT03278509 - Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART) Phase 4
Completed NCT03156699 - The Incidence, Effect and Persistence of Fragmented-QRS, in Patients Presenting With ST-Elevation Myocardial Infarction
Not yet recruiting NCT03266328 - Procedure and In-hospital Outcome of Patients Under 40 Years Old Undergoing Primary Percutaneous Coronary Intervention for Acute ST Elevated Myocardial Infarction in Assiut University N/A
Not yet recruiting NCT03263468 - Revascularization StrategIes for ST Elevation Myocardial Infarction Trial N/A
Not yet recruiting NCT05605288 - Distal Versus Conventional Transradial Artery Access for Coronary Catheterization in Patients With STEMI N/A
Enrolling by invitation NCT04970238 - Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction Phase 4
Recruiting NCT02557217 - NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction Phase 2
Recruiting NCT02224534 - Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction Phase 4
Completed NCT01136187 - Trial Comparing Radial and Femoral Approach in Primary Percutaneous Coronary Intervention (PCI) N/A
Not yet recruiting NCT04068116 - Impact of Ischemic Post-conditioning N/A
Not yet recruiting NCT04063345 - Long-term Clinical Outcomes of intraVascular Ultrasound-guided vs Angiography-guided Primary pErcutaneous Intervention in Patients With Acute ST Segment Elevated Myocardial Infarction Phase 2/Phase 3
Active, not recruiting NCT03646357 - BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function Phase 4
Completed NCT03984071 - The Predictive Value of eGFR for Adverse Cardiovascular Events in Patients With STEMI